Target- |
Mechanism- |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhaseIND Application |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ RecruitingEarly Phase 1 A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients with Advanced Solid Tumors
The purpose of this clinical trial is to evaluate the safety and tolerability of SXRN Plasmid DNA Technique in patients with advanced solid tumors.
100 Clinical Results associated with Jiangsu Nutai Biologics Co., Ltd.
0 Patents (Medical) associated with Jiangsu Nutai Biologics Co., Ltd.
100 Deals associated with Jiangsu Nutai Biologics Co., Ltd.
100 Translational Medicine associated with Jiangsu Nutai Biologics Co., Ltd.